A new report from The Coalition for Affordable Prescription Drugs (CAPD) and conducted by Matrix Global Advisors (MGA) found the yearly cost of big drug companies’ patent thickets on five top-selling prescription drugs ranges from $1.8 to $7.6 billion each. The study highlights that “many companies delay or block more affordable competitors from entering the market for far
WASHINGTON — Pharmaceutical Care Management Association President and CEO JC Scott issued the following statement on a new report by the U.S. Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE), Office of Health Policy, showing that minorities in Medicare are the most likely to experience prescription drug affordability problems. “The Administration’s research on
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Ways and Means Committee’s inclusion of full repeal of the rebate rule in the committee’s “Build Back Better Act:” “We applaud chairman Richard Neal, and members of the Ways and Means Committee, for including a permanent repeal
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Biden administration’s plan for high drug prices: “While we review the recently released Comprehensive Plan for Addressing High Drug Prices report, America’s pharmacy benefit managers, PBMs, applaud the Administration for its focus on reducing prescription drug costs for patients
WASHINGTON — As the “National Call-In Day” takes place in support of the bipartisan “Mainstreaming Addiction Treatment Act,” reintroduced in February by U.S. Senators Maggie Hassan (D-NH) and Lisa Murkowski (R-AK) and Representatives Paul D. Tonko (D-NY) and Michael Turner (R-OH), Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott released the following statement:
WASHINGTON — Today, the Pharmaceutical Care Management Association (PCMA) announced the Virtual PBM Policy Forum 2021, featuring health care, pharmacy benefit managers (PBMs), and pharmaceutical manufacturer industry thought leaders and executives discussing how the public and private sectors are tackling drug costs and improving the affordability and quality of care for patients. “We are pleased
WASHINGTON — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers use “patent thickets” to block generic or biosimilar competition from entering the market. For Humira, Enbrel,
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is announcing a new three-part policy platform, supported by America’s pharmacy benefit managers, PBMs, aimed at reducing prescription drug costs by updating Medicare Part D, enhancing competition, and building toward a more value-driven health care system for patients. “PCMA’s multi-faceted policy platform provides specific policy actions to
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the pending confirmations of three officials of the U.S. Department of Health and Human Services (HHS): Chiquita Brooks-LaSure, nominee for Administrator for the Centers for Medicare & Medicaid Services; Andrea Palm, nominee for Deputy Secretary; Melanie Egorin, nominee
WASHINGTON — A new white paper, “Solving America’s High Drug Cost Problem: Prevent Drug Company Tactics that Increase Costs and Undermine Clinical Quality,” by the Pharmacy Benefit Management Institute (PBMI), released today by the Pharmaceutical Care Management Association (PCMA), outlines ways that some drug manufacturers undermine formulary and utilization management tools, resulting in higher drug costs
WASHINGTON — In recognition of National Diabetes Month, the Pharmaceutical Care Management Association (PCMA) is outlining how pharmacy benefit managers, PBMs, are working to lower insulin costs and creating programs to support people with diabetes and improve health outcomes. “PBMs have been able to moderate insulin costs for most people with insurance,” said PCMA president and CEO
ALEXANDRIA, Va. — Groups ranging from the National Community Pharmacists Association (NCPA) to the Food Industry Association (FMI) have applauded the Supreme Court for hearing Rutledge v. Pharmaceutical Care Management Association (PCMA). This historic case seeks to clarify whether states can regulate pharmacy benefit managers, which manage prescription drug benefits for health insurers, Medicare Part
WASHINGTON— Pharmaceutical Care Management Association president and CEO JC Scott issued the following statement on the open enrollment season for the Medicare Part D prescription drug benefit: “As open enrollment begins, we are encouraged to see the continued trend of affordability and low premiums for seniors under Medicare Part D. This trend in affordability is due
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the Administration’s announcement on 2021 Medicare Part D premiums: “PCMA applauds the Administration for its work continuing the success of the Part D program. Today’s announcement shows that the 2021 and 2020 average basic premiums are the second
